Gastro-oesophageal reflux disease, Irritable bowel syndrome, Dyspepsia
Adult: 25 mg tid.
Elderly: Dose reductions may be necessary.
Elderly: Dose reductions may be necessary.
Indications and Dosage
Oral
Gastro-oesophageal reflux disease, Irritable bowel syndrome, Dyspepsia Adult: 25 mg tid.
Elderly: Dose reductions may be necessary. |
Contraindications
Phaeochromocytoma, epilepsy, manic states, hyperprolactinaemia, mammary dysplasia, malignant mastopathies, cardiac impairment. GI bleeding, mechanical obstruction or perforation.
|
Special Precautions
May impair ability to drive or operate machinery. Pregnancy and lactation.
|
Adverse Reactions
Amenorrhoea, gynaecomastia, galactorrhoea, changes in libido.
Potentially Fatal: Neuroleptic malignant syndrome. |
Drug Interactions
Reduced bioavailability with sucralfate, aluminium- and magnesium-containing antacids. Effect on GI motility may be antagonised by anticholinergic agents, narcotics and analgesics. Avoid alcohol.
|
Action
Description:
Mechanism of Action: Levosulpiride is a substituted benzamide, which exerts antidopaminergic (selective dopamine D2 receptors) activity on both central and peripheral levels. It is an atypical neuroleptic and a prokinetic agent. Pharmacokinetics: Absorption: Oral bioavailability is about 30%; peak plasma concentrations after about 3 hr. Excretion: Mainly via urine. Plasma half-life: 9.7 hr (oral); 4.3 hr (IV). |
Storage
Store at 15-30°C (59-86°F).
|
MIMS Class
|